Lv23
140 积分 2022-11-11 加入
Animal models for development of anti-obesity drugs in the Age of GLP-1 Agents
8天前
已完结
Amylin takes another shot at the obesity prize
5个月前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
5个月前
已完结
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial
1年前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
1年前
已完结
Derivatization with fatty acids in peptide and protein drug discovery
2年前
已完结
The ‘breakthrough’ obesity drugs that have stunned researchers
2年前
已完结
In type 2 diabetes, tirzepatide reduced HbA1c vs. semaglutide
2年前
已完结
LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
2年前
已完结
Efficient synthesis of Aib 8 ‐Arg 34 ‐GLP‐1 (7–37) by liquid‐phase fragment condensation
3年前
已完结
皖公网安备34019202002308
